Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
J Biol Regul Homeost Agents ; 33(6 Suppl. 2): 93-101. DENTAL SUPPLEMENT, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-32425029

RESUMO

Turning to peeling in a dermatological sphere is extensively common and has been used for a long time. From the use of single acids moving on to the so-called compound peelings (associations of more than one substance in the same product) and the combined peelings which take advantage of the action of different substances in a synergistic manner (different products are applied sequentially) in order to best guarantee a greater effectiveness of the treatment for the recommended target. Superficial peelings, combined and not, have led to a drastic reduction in the percentage of incidence of adverse events typical of medium and deep peels. Nevertheless, it has been demonstrated that superficial peels bring about a rejuvenating effect through the mechanical stimulation of the Skin Stress Response System (SSRS), system designated to repairing the damaged tissue and restoring of the normal homeostasis. Clinical trials aims to evaluate the effectiveness and safety of the peppermint peel (PMP) medical device in subjects with different ageing expressions both in qualitative terms (different blemishes such as discolouration, fine wrinkles, elastosis, atony and skin inelasticity, laxity, scarce superficial hydration) and in quantitative terms (degree, extension and number of lesions). A non-controlled multi-centric clinical trial was done in 121 subjects. The use protocol calls for a session every 2 weeks for a total of 4 sessions. Subjects were evaluated before each subsequent session at the first and at 2-4-8 weeks of the fourth and last treatment. During the study there were no adverse events. Only a minimal scurfy flaking and a very slight redness were reported. From an effectiveness point of view, the percentage of therapeutic failure, judged with a score equal to or greater than 4 or 5 in Global Aesthetic Improvement Scale (GAIS) scale was 0%. Best score was obtained in subjects ranging in ages between 38 and 57 (2.02) and in women (2.02) years, while the less satisfactory one was obtained in males (2.14). The study has demonstrated that PMP and the proposed protocol are effective and safe to treat subject with skin signs of chrono and photo ageing, thanks to its capabilities of carrying out a mechanic action indicated as a coadjuvant in the treatment of the dermoepidermic revitalisation through chemical exfoliation and hydration.


Assuntos
Abrasão Química , Mentha piperita/química , Envelhecimento da Pele/efeitos dos fármacos , Adulto , Estética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pele
2.
Ann Hematol ; 84(3): 167-76, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15592833

RESUMO

This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb < or =10 g/dl. Epoetin alfa 40,000 IU was given subcutaneously twice weekly; after 4 weeks, the dose could be reduced to 40,000 IU weekly in patients achieving erythroid response. QOL was assessed using the functional assessment of cancer therapy-anemia (FACT-An) questionnaire. FACT-An scores increased on average by 7.5 after 4 weeks and by 8.8 after 8 weeks compared with baseline. FACT-An scores were positively associated with Hb values (r=0.53, P<0.01). The mean FACT-An score increase at week 8 was 10.2 in responders and 5.6 in nonresponders. The overall erythroid response rate at week 8 was 68%: 74% in transfusion-independent patients and 59% in transfusion-dependent patients. Of all responders at week 8, response was maintained in 86% at week 12, 71% at week 16, 65% at week 20, and 54% at week 24. Treatment was generally well tolerated. Our data provide new and encouraging results regarding the benefits of 40,000 IU biweekly induction doses followed by 40,000 IU weekly in improving QOL, correcting anemia, and reducing transfusion requirements in low-risk MDS patients.


Assuntos
Anemia/tratamento farmacológico , Eritropoetina/administração & dosagem , Síndromes Mielodisplásicas/complicações , Qualidade de Vida , Adulto , Idoso , Idoso de 80 Anos ou mais , Anemia/etiologia , Transfusão de Sangue , Epoetina alfa , Feminino , Hemoglobinas/análise , Humanos , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/sangue , Síndromes Mielodisplásicas/tratamento farmacológico , Proteínas Recombinantes , Risco , Inquéritos e Questionários
3.
Hemoglobin ; 24(3): 227-37, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10975442

RESUMO

Hb Peterborough [beta111(G13)Val-->Phe], an unstable hemoglobin variant with low oxygen affinity, was first described in two patients of Italian origin. This paper reports the first observation of this variant in Campania, Southern Italy, in two unrelated patients suffering from mild anemia. The variant was separated from Hb A by cation exchange chromatography on a high performance liquid chromatographic system with an automated procedure that might be useful for diagnostic purposes. The amino acid replacement, Val-Phe at [beta111, was assessed by tandem electrospray mass spectrometry analysis, and the corresponding DNA mutation was established as G-->T at the first position of codon 111 (GTC-TTC) by polymerase chain reaction amplification techniques. A family study showed that the two original carriers of Hb Peterborough were members of the same family as the proband examined in this study. This finding, and the presence of a second unrelated family carrying Hb Peterborough in Campania, strongly suggests that the DNA mutation associated with this variant originated in Southern Italy.


Assuntos
Hemoglobinas Anormais/genética , Mutação , Adulto , Sequência de Aminoácidos , Substituição de Aminoácidos , Cromatografia Líquida de Alta Pressão , Análise Mutacional de DNA , Eletroforese , Saúde da Família , Feminino , Variação Genética , Haplótipos , Testes Hematológicos , Hemoglobinas Anormais/efeitos adversos , Hemoglobinas Anormais/química , Humanos , Itália , Dados de Sequência Molecular , Linhagem , Espectrometria de Massas por Ionização por Electrospray
4.
Gene Ther ; 7(14): 1234-7, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10918492

RESUMO

The activity of NF-kappa B/Rel nuclear factors is known to inhibit apoptosis in various cell types. We investigated whether the subtraction of NF-kappa B/Rel activity influenced the response of 11 AML (M1, M2 and M4) patients' cells to AraC. To this end we used a phosphorothioate double-stranded decoy oligodeoxynucleotide (ODN) carrying the NF-kappa B/Rel- consensus sequence. Cell incubation with this ODN, but not its mutated (scrambled) form used as a control, resulted in abating the NF-kappa B/Rel nuclear levels in these cells, as verified by electrophoretic mobility shift assay (EMSA) of cells' nuclear extracts. We incubated the leukemic cells with AraC (32 or 1 microM), in either the absence or presence of the decoy or the scrambled ODN, and analyzed cell apoptosis. The spontaneous cell apoptosis detectable in the absence of AraC (<25%) was not modulated by the oligonucleotide presence in cell cultures. On the other hand, in 10 of the 11 samples tested, the decoy kappa B, but not the scrambled ODN significantly (P < 0.01 in a Student's t test) enhanced cell apoptotic response to AraC. Such an effect was particularly remarkable at low AraC doses (1 microM). These findings indicate that NF-kappa B/Rel activity influences response to AraC in human primary myeloblastic cells, and suggests that the inhibition of NF-kappa B/Rel factors can improve the effect of chemotherapy in AML. Gene Therapy (2000) 7, 1234-1237.


Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Citarabina/uso terapêutico , Leucemia Mieloide Aguda/patologia , Oligodesoxirribonucleotídeos/genética , Apoptose/efeitos dos fármacos , Genes rel/fisiologia , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , NF-kappa B/fisiologia , Células Tumorais Cultivadas
5.
Fam Plann Perspect ; 32(2): 56-64, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10779236

RESUMO

CONTEXT: Helping high-risk pregnant women obtain prenatal care early is the main policy goal of most U.S. publicly funded programs aimed at reducing the incidence of low birth weight and infant mortality It is therefore crucial to understand the factors that influence when women initiate prenatal care. METHODS: The effects of psychosocial and demographic risk factors on the timing of entry into prenatal care were estimated using data on roughly 90,000 Medicaid recipients who participated in New Jersey's HealthStart prenatal care program. RESULTS: Overall, 37% of women began prenatal care in the first trimester. Multivariate logistic regression indicated that women who lived in poor housing conditions and those who smoked, drank or used hard drugs had a reduced likelihood of entering care early (odds ratios, 0.8-0.9), while those who had clinical depression or who experienced domestic violence or abuse had elevated odds of early entry (1.1-1.2). The risk factor with the greatest impact on the timing of prenatal care was the wantedness of the pregnancy; women whose pregnancy was unwanted had dramatically reduced odds of entering care early (0.4). Separate analyses of women of varying racial and ethnic backgrounds demonstrated the differential effects of risk factors, the importance of including ethnicity with race and the universal impact of wantedness across racial and ethnic groups. CONCLUSIONS: Entry into prenatal care for at-risk women is affected by factors from multiple domains. It is important for prenatal programs to recognize the complexity of the issue as well as the barriers that different subgroups of women face.


Assuntos
Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Cuidado Pré-Natal/estatística & dados numéricos , Adolescente , Adulto , Peso ao Nascer , Demografia , Feminino , Pesquisa sobre Serviços de Saúde , Humanos , Medicaid , Análise Multivariada , New Jersey , Aceitação pelo Paciente de Cuidados de Saúde/etnologia , Gravidez , Fatores Socioeconômicos , Estados Unidos
6.
J Health Econ ; 18(2): 241-57, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10346355

RESUMO

The appropriations for North Carolina's abortion fund have proven inadequate during five of the years between 1980 and 1994. This on-again, off-again funding pattern provides a natural experiment for estimating the short-run effect of changes in the cost of abortions on the number of abortions to indigent women. Using an unusually detailed dataset, we estimate the effects of funding termination on the monthly abortion and birth rates. Overall, approximately one-third of pregnancies that would have resulted in an abortion, had state funds been available, are instead carried to term.


Assuntos
Aborto Legal/economia , Financiamento Governamental/tendências , Resultado da Gravidez , Aborto Legal/estatística & dados numéricos , Adolescente , Adulto , Coeficiente de Natalidade , Criança não Desejada , Redução de Custos , Feminino , Humanos , Indigência Médica , North Carolina , Pobreza , Gravidez
7.
Leuk Lymphoma ; 30(1-2): 153-62, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9669685

RESUMO

The superiority of intensive versus standard chemotherapy for aggressive (I: intermediate; H: high grade) NHL is still debated; increased antitumor activity may be counterbalanced by increased toxicity. We have designed a first-line five-drug regimen (vincristine, idarubicin, cyclophosphamide, etoposide and deflazacort), with the aim of potentiating the CHOP protocol without losing tolerability and ease of administration. Seventy-one patients (33% aged > or = 65) entered the study. CR was obtained in 66.7% of patients (I: 74%; H: 56%), PR in 19.7%: overall response rate was 86.4%. Six patients were resistant, two died during treatment. With a median follow up of two years, relapse has occurred in 14 patients (8 I, 6 H). At 3 years, overall survival was projected to be 62.5% (I 73.5%; H 31.4%), disease free survival 66% (I 71%, H 56.3%). No organ toxicity occurred. Myelosuppression was moderate, with a nadir on the 14th day. Febrile episodes occurred in 16% of courses, dose delay in 19% of courses; dose reduction in 3% of patients. No patient required hospitalization. G-CSF was only occasionally used. This regimen has shown a potent antitumor effect with an excellent tolerance, even in elderly patients.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma não Hodgkin/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ciclofosfamida/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Humanos , Idarubicina/administração & dosagem , Linfoma não Hodgkin/mortalidade , Linfoma não Hodgkin/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Taxa de Sobrevida , Resultado do Tratamento , Vincristina/administração & dosagem
8.
Fam Plann Perspect ; 29(6): 268-72, 295, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9429872

RESUMO

The effects of maternal age on low birth weight, newborns' hospital costs and infant mortality were estimated based on individual 1989 and 1990 vital statistics records from New Jersey that were linked with uniform billing hospital discharge records. Results of multivariate analyses show a U-shaped relationship between maternal age and low birth weight among whites, with the youngest (younger than 15) and oldest (aged 40 and older) mothers being at higher risk than 25-29-year-olds; older teenagers were not at any significantly increased risk. Among blacks, however, 15-19-year-olds faced significantly lower risks of delivering low-birth-weight babies than did black women aged 25-29. Both black and white mothers in their 30s were significantly more likely to deliver a low-birth-weight baby than women aged 25-29 of the same race. The multivariate analysis also showed that newborn hospitalization costs increased with maternal age among both blacks and whites. The seemingly poorer birth outcomes of teenage mothers appear to result largely from their adverse socioeconomic circumstances, not from young maternal age per se.


PIP: This study compared birth outcomes among Black and White adolescents aged under 15 years, 15-17 years, and 18-19 years, in New Jersey. Data were obtained from vital statistics records for 1989 and 1990, and hospital discharge records from the New Jersey Department of Health. Hospital discharge records included insurance status and newborn costs. Adolescent data was compared to data among women aged 20-40 years. The 3 models run separately for each race were ones that allowed for the gross effects of age, controls for medical and behavioral risk factors only, and controls for socioeconomic status. Birth outcomes included infant mortality, low birth weight (LBW), and newborn costs. Findings indicate a complex set of relationships between maternal age, comparison groups, birth outcomes, and mediating factors. The analysis among White adolescents supports the common perception that teenage mothers are at higher risk of unfavorable birth outcomes and higher hospital costs than women in their 20s, but not all older women. Teenagers aged under 15 years had the highest risk of delivering a LBW infant compared to women aged 15-19 years, followed by mothers aged 40 years and older and women aged 35-39 years. Newborn costs among White and Black teenagers were lower than costs to older women. One caveat is that many teenagers are not at any increased risk of adverse birth outcomes, and unobserved determinants of adverse outcome could be related to prenatal care, smoking, or alcohol use. Black teenagers had a significantly reduced risk of having an LBW compared to 25-29 year olds. Poorer outcomes are attributed to adverse socioeconomic conditions. White teenagers aged under 15 years had the most unexplained risk. Risk of infant mortality increased with the increasing age of the mother, particularly among Black women. Rates of LBW among Black women aged 15-19 years were 3 times higher than among Whites.


Assuntos
Idade Materna , Resultado da Gravidez , Gravidez na Adolescência , Adolescente , Adulto , Negro ou Afro-Americano/estatística & dados numéricos , Feminino , Preços Hospitalares , Humanos , Mortalidade Infantil , Recém-Nascido de Baixo Peso , Recém-Nascido , Análise Multivariada , New Jersey/epidemiologia , Razão de Chances , Gravidez , Análise de Regressão , História Reprodutiva , Fatores de Risco , Fatores Socioeconômicos , População Branca/estatística & dados numéricos
9.
Am J Hum Genet ; 59(4): 887-95, 1996 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8808605

RESUMO

X-chromosome inactivation in mammals is regarded as an essentially random process, but the resulting somatic-cell mosaicism creates the opportunity for cell selection. In most people with red-blood-cell glucose-6-phosphate dehydrogenase (G6PD) deficiency, the enzyme-deficient phenotype is only moderately expressed in nucleated cells. However, in a small subset of hemizygous males who suffer from chronic nonspherocytic hemolytic anemia, the underlying mutations (designated class I) cause more-severe G6PD deficiency, and this might provide an opportunity for selection in heterozygous females during development. In order to test this possibility we have analyzed four heterozygotes for class I G6PD mutations: two with G6PD Portici (1178G-->A) and two with G6PD Bari (1187C-->T). We found that in fractionated blood cell types (including erythroid, myeloid, and lymphoid cell lineages) there was a significant excess of G6PD-normal cells. The significant concordance that we have observed in the degree of imbalance in the different blood-cell lineages indicates that a selective mechanism is likely to operate at the level of pluripotent blood stem cells. Thus, it appears that severe G6PD deficiency affects adversely the proliferation or the survival of nucleated blood cells and that this phenotypic characteristic is critical during hematopoiesis.


Assuntos
Deficiência de Glucosefosfato Desidrogenase/genética , Glucosefosfato Desidrogenase/sangue , Glucosefosfato Desidrogenase/genética , Mutação Puntual , Autorradiografia , Células Sanguíneas/enzimologia , Mecanismo Genético de Compensação de Dose , Feminino , Ligação Genética , Deficiência de Glucosefosfato Desidrogenase/sangue , Deficiência de Glucosefosfato Desidrogenase/enzimologia , Hematopoese , Heterozigoto , Humanos , Mosaicismo , Fenótipo , Reação em Cadeia da Polimerase , RNA Mensageiro/metabolismo , Cromossomo X
10.
J Chemother ; 8(5): 399-402, 1996 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8957722

RESUMO

A major problem in cancer treatment is the progressive desensitization of the cancer cells to chemotherapeutic drugs. Several hypotheses have been advanced to explain this property of neoplastic cells. In recent years, some calcium-channel blockers have successfully been used to restore drug-sensitivity in previously resistant tumors. The presence of a correlation between ion channels and membrane fluidity is well known. In the ambit of our studies on the activity of several chemotherapeutic drugs on tumors, we have studied the variations in membrane depolarization and fluidity in some leukemic cells as a result of polychemotherapeutic treatments. Our results demonstrate that the membrane fluidity and K(+)-induced depolarization of some types of leukemic cells in patients untreated and treated with some chemotherapeutic agents, are altered significantly as compared to those of normal leukocytes.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doenças Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/tratamento farmacológico , Leucócitos/efeitos dos fármacos , Fluidez de Membrana/efeitos dos fármacos , Estudos de Casos e Controles , Doenças Hematológicas/sangue , Neoplasias Hematológicas/sangue , Humanos , Potenciais da Membrana/efeitos dos fármacos
11.
AJS ; 101(6): 1694-718, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-11613292

RESUMO

Using oral histories collected in 1938 and 1939 in the Southern United States, this article examines how African-Americans and whites viewed marriage and nonmarital childbearing. The authors document distinct racial differences in family norms and the sanctions that supported those norms. Giving birth outside a marital relationship was clearly not the stigmatizing event for African-Americans that it was for whites. The authors also found that African-Americans were more likely than whites to end marriages under similar conditions. These results suggest that debates about contemporary racial differences need to take into account the historical background, both cultural and demographic, of diverse groups.


Assuntos
Negro ou Afro-Americano/história , Família , Fertilidade , Casamento/história , História do Século XX , Humanos , Grupos Raciais/história , Estados Unidos
12.
Br J Haematol ; 80(1): 111-6, 1992 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1536798

RESUMO

More than 80 genetic variants of glucose-6-phosphate dehydrogenase (G6PD) are associated with chronic non-spherocytic haemolytic anaemia (CNSHA). In order to help clarify the molecular basis of this association, we have carried out a detailed biochemical and genetic characterization of two G6PD deficient brothers affected by CNSHA. The G6PD from the two patients has altered electrophoretic mobility, abnormally elevated Michaelis constant (Km) for G6P, and extreme instability in vivo and in vitro. By comparison with published information we found that this is a new G6PD variant which we have designated G6PD Portici. The entire coding region of the gene has been sequenced, and a single point mutation, a G----A transition, was found at position 1178 in exon X, causing a substitution of histidine for arginine at residue 393 in the polypeptide chain. By polymerase chain reaction (PCR) amplification followed by diagnostic restriction enzyme analysis and allele-specific oligonucleotide hybridization we have demonstrated the inheritance of this mutation in the patient's family. Our results support the notion of a causative link between this mutation in the G6PD gene and CNSHA. Our data, in combination with previous data in the literature, suggest that the three-dimensional structure of G6PD is such as to cause interaction in the binding of its two substrates, G6P and NADP.


Assuntos
Anemia Hemolítica Congênita não Esferocítica/genética , Deficiência de Glucosefosfato Desidrogenase/genética , Glucosefosfato Desidrogenase/genética , Adolescente , Anemia Hemolítica Congênita não Esferocítica/enzimologia , Doença Crônica , DNA/análise , Glucosefosfato Desidrogenase/metabolismo , Deficiência de Glucosefosfato Desidrogenase/enzimologia , Humanos , Masculino , Mutação , Linhagem
16.
Artigo em Inglês | MEDLINE | ID: mdl-64434

RESUMO

The still increasing amount of carriers and anemics by thalassemia (Th) and other Hb-pathies (approximately 4,000 among approximately 48,000 investigated people) have shown that Campania is the most affected world area by all Hb Lepre conditions. Among 161 people with heterozygous Hb Lepore we have noticed 10 cases associated with (hemo-) blastomata as follows: 2 Chr. Lymphatic Leukemia, 2 Ac. Lymphoblastic Leukemia, 1 Lymphosarcom, 1 Colon Cancer, 1 Uterin Cancer, 1 Plasmocytom, 1 Hodkgin Disease, 1 Ac. Promyelocyte Leukemia (or fatal ac. agranulocytemia?). In the literature we recently found 2 other similar cases. The incidence of such malignancies in our Hb Lepore people reaches 6%. On the contrary in the heterozygous Th. group, among 3,150 carriers, we diagnosed only 20 people with (hemo-) blastomata as follows: 12 Ac. Leukemia (9Lymphoblastic) and 8 Chr. Myeloid Leukemia, with an incidence rate of 0.6% namely a little higher than in normal people. This highly significant discrepancy rate shows an elective predisposition to (haemo-) blastomata from Leporian people.


Assuntos
Hemoglobinas Anormais , Leucemia/sangue , Neoplasias do Colo/sangue , Feminino , Genótipo , Hemoglobinopatias/imunologia , Heterozigoto , Doença de Hodgkin/sangue , Homozigoto , Itália , Linfoma não Hodgkin/sangue , Plasmocitoma/sangue , Talassemia/sangue , Neoplasias Uterinas/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...